June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Topline results from prospective, double-masked, placebo controlled phase 2b clinical study evaluating Luminate® in patients with diabetic macular edema
Author Affiliations & Notes
  • Peter K Kaiser
    Division of Ophthalmology, Cole Eye Institute, Whippany, New Jersey, United States
  • David S Boyer
    Retina Vitreous Assoc Med Group, Los Angeles, California, United States
  • Peter A Campochiaro
    Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States
  • Jeffrey Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
  • Julie Kornfield
    Caltech, Pasadena, California, United States
  • Baruch D Kuppermann
    Gavin Herbert Eye Institute, Irvine, California, United States
  • Hugo Quiroz-Mercado
    Department of Ophthalmology, University of Colorado, Aurora, Colorado, United States
  • Lisa Karageozian
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Linda Kutscher
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Mary Karpus
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • John Y Park
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Hampar L Karageozian
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Vicken Karageozian
    Allegro Ophthalmics, LLC, San Juan Capistrano, California, United States
  • Footnotes
    Commercial Relationships   Peter Kaiser, Allegro Ophthalmics (I), Allegro Ophthalmics (C); David Boyer, Aerpio (C), Alcon (C), Alimera Sciences (C), Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allergan (C), Bausch+Lomb (C), Bayer (C), Boehringer Ingelheim Pharmaceuticals (C), CoDa Therapeutics (C), Foresight Biotherapeutics (C), Genentech (C), GenSight Biologics (C), GlaxoSmithKline (C), GrayBug Vision (C), Neurotech (C), Novartis Ophthalmics (C), Nuerotech (I), Ocular Therapeutics (C), Ohr (C), Ohr (I), Ophthotech (C), Ophthotech (I), Regeneron (C), Roche (C); Peter Campochiaro, Aerpio Therapeutics (F), Aerpio Therapeutics (C), Alimera (F), Alimera (C), Allegro Ophthalmics (F), Allegro Ophthalmics (I), Allegro Ophthalmics (C), Allergan (F), Allergan (C), Applied Genetic Technologies (C), AsclipiX (F), AsclipiX (C), Genentech/Roch (F), Genentech/Roch (C), Genzyme (F), GrayBug (C), GrayBug (I), Intrexon (C), Merck (C), Oxford Biomedica (F), Regeneron (F), Regenxbio (F), Regenxbio (C), Rxi (F), Rxi (C); Jeffrey Heier, Aerpio (C), Alimera (C), Allegro Ophthalmics (I), Allegro Ophthalmics (C), Allergan (C), EyeGate (C), EyeGate (F), Genentech (F), Genentech/Roche (C), Kala (C), Novartis (F), Regeneron (C), Regeneron (F), Scifluor (C), Scifluor (F), Shire (C), Stealth Biotherapeutics (C); Julie Kornfield, Allegro Ophthalmics (C), Allegro Ophthalmics (I); Baruch Kuppermann, Aerpio (C), Alcon (C), Alcon (F), Alimera (C), Alimera (F), Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allegro Ophthalmics (F), Allergan (C), Allergan (F), Ampio (C), Apellis (F), Dose (C), Eleven Biotherapeutics (C), Genentech (C), Genentech (F), Glaukos (C), Lumenis (C), Novartis (C), Ohr (F), Ophthotech (C), Ophthotech (F), Regeneron (C), Regeneron (F), ThromboGenics (F); Hugo Quiroz-Mercado, Allegro Ophthalmics (C), Allegro Ophthalmics (I); Lisa Karageozian, Allegro Ophthalmics (I), Allegro Ophthalmics (E); Linda Kutscher, Allegro Ophthalmics (I), Allegro Ophthalmics (E); Mary Karpus, Allegro Ophthalmics (I), Allegro Ophthalmics (E); John Park, Allegro Ophthalmics (I), Allegro Ophthalmics (E), Allegro Ophthalmics (P); Hampar Karageozian, Allegro Ophthalmics (I), Allegro Ophthalmics (E), Allegro Ophthalmics (P); Vicken Karageozian, Allegro Ophthalmics (I), Allegro Ophthalmics (E), Allegro Ophthalmics (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2029. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Peter K Kaiser, David S Boyer, Peter A Campochiaro, Jeffrey Heier, Julie Kornfield, Baruch D Kuppermann, Hugo Quiroz-Mercado, Lisa Karageozian, Linda Kutscher, Mary Karpus, John Y Park, Hampar L Karageozian, Vicken Karageozian; Topline results from prospective, double-masked, placebo controlled phase 2b clinical study evaluating Luminate® in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2029.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Luminate® is an RGD class synthetic anti-integrin oligopeptide. Studies have shown that it inhibits integrin receptors in vitro and arrests aberrant blood vessel growth in vivo meditated by αvβ3, αvβ5 as well as α2β1 and α5β1 - integrin sites that are expressed in neovascular ocular tissue from patients with diabetic retinopathy. A more recent Phase 1 study demonstrated its safety when injected intravitreally in human subjects with diabetic macular edema (DME). The purpose of this Phase 2b study was to investigate the safety and efficacy of Luminate, as compared to Avastin® (bevacizumab), administered intravitreally in patients with DME.

Methods : 136 patients from 32 U.S. sites were randomly assigned to four groups. Groups received 1.0 mg, 2.0 mg, or 3.0 mg of Luminate, or 1.25 mg of Avastin. The Luminate groups received 3 monthly intravitreal injections (week 0, 4, and 8) while the Avastin group received up to 6 monthly injections (week 0, 4, 8, 12, 16, 20). The efficacy outcomes were change (from baseline) in BCVA and central macular thickness (CMT) at week 20. The safety outcomes were adverse events.

Results : At study week 20, continuous monthly Avastin was compared to 12 weeks post loading with Luminate. The mean (SD) change in BCVA were 5.2(6.86), 2.7(7.31), -1.5(9.97) and 7.0(8.21) letters gained in 1.0 mg, 2.0 mg and 3.0 mg Luminate versus 1.25 mg Avastin, respectively. The mean (SD) change in CMT were -77(141), -16(110), -1(152) and -104(107)μm, respectively. There were no drug related serious adverse events in the Luminate groups.

Conclusions : Data from this Phase 2b DME trial demonstrated that Luminate met its primary and secondary endpoints of BCVA and CMT change at study week 20. Three doses of Luminate demonstrated non-inferiority to 6 doses of Avastin (≤3 letters difference in BCVA and ≤30mm difference in CMT) at the primary endpoint of 20 weeks. Moreover, Luminate showed 12 week durability from the last dose in monotherapy use. Consistent with prior animal work, Luminate appears to have a U-shaped dose response curve with decreasing efficacy with increasing dosing above 1.0 mg Luminate.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×